## Nuria López-Ariztegui

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1039572/publications.pdf

Version: 2024-02-01

1163117 940533 21 294 8 16 g-index citations h-index papers 25 25 25 261 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Clinical utility of a personalized and long-term monitoring device for Parkinson's disease in a real clinical practice setting: An expert opinion survey on STAT-ONâ,, e. NeurologÃa, 2023, 38, 326-333.	0.7	7
2	Constipation Predicts Cognitive Decline in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group. Journal of Parkinson's Disease, 2022, 12, 315-331.	2.8	10
3	Parkinson's Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Parkinson's Disease, 2022, 12, 935-955.	2.8	3
4	Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson's Disease Patients: A 2-Year Follow-Up Study. Diagnostics, 2022, 12, 1147.	2.6	5
5	Sleep Problems Are Related to a Worse Quality of Life and a Greater Non-Motor Symptoms Burden in Parkinson's Disease. Journal of Geriatric Psychiatry and Neurology, 2021, 34, 642-658.	2.3	15
6	Depression is Associated with Impulse-compulsive Behaviors in Parkinson's disease. Journal of Affective Disorders, 2021, 280, 77-89.	4.1	9
7	Falls Predict Acute Hospitalization in Parkinson's Disease. Journal of Parkinson's Disease, 2021, , 1-20.	2.8	5
8	«El convento de las monjas torcidas». SÃndrome de Pisa y camptocormia inducido por antipsicóticos. Neurocirugia, 2021, 32, 148-152.	0.4	1
9	Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life. Parkinson's Disease, 2021, 2021, 1-16.	1.1	10
10	Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Personalized Medicine, 2021, 11, 626.	2.5	10
11	Predictors of Loss of Functional Independence in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group. Diagnostics, 2021, 11, 1801.	2.6	9
12	Predictors of clinically significant quality of life impairment in Parkinson's disease. Npj Parkinson's Disease, 2021, 7, 118.	5.3	17
13	Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. Diagnostics, 2021, 11, 2380.	2.6	2
14	Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson's disease. BMC Neurology, 2021, 21, 477.	1.8	7
15	Non-motor symptom burden in patients with Parkinson's disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort. Scientific Reports, 2020, 10, 16893.	3.3	6
16	Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression. Journal of the Neurological Sciences, 2020, 418, 117109.	0.6	11
17	Nonâ€motor symptom burden is strongly correlated to motor complications in patients with Parkinson's disease. European Journal of Neurology, 2020, 27, 1210-1223.	3.3	40
18	The impact of freezing of gait on functional dependency in Parkinson's disease with regard to motor phenotype. Neurological Sciences, 2020, 41, 2883-2892.	1.9	13

# /	Article	IF	CITATIONS
19 t	Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort. Parkinsonism and Related Disorders, 2019, 66, 151-157.	2.2	71
•	<scp>COPPADIS</scp> â€2015 ( <scp>CO</scp> hort of Patients with PArkinson's <scp>DI</scp> sease in) Tj ETQc	0 0 0 rgB	Γ/Overlock
	1000 subjects included. Results from the baseline evaluation. European Journal of Neurology, 2019, 26, 1399-1407.	3.3	32
21 [	Central Levodopa Influx and the Clinical Motor Response to Levodopa in Patients With Parkinson Disease Complicated With Motor Fluctuations and Dyskinesias. Clinical Neuropharmacology, 2009, 32, 321-325.	0.7	2